Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
NCT00887575
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
1. Female patients, age ≥18 years
2. Histologically confirmed invasive ER-, PR-, and HER2-negative (triple-negative) adenocarcinoma of the breast
3. Triple-negative tumors are defined as:
- For HER2-negative:
- Fluorescence in situ hybridization (FISH)-negative (defined by ratio <2.2) OR
- Immunohistochemical (IHC) 0, IHC 1+, OR
- IHC 2+ or IHC 3+ and FISH-negative (defined by ratio <2.2)
- For ER- and PR-negative: <10% tumor staining by immunohistochemistry (IHC)
4. Primary palpable disease confined to a breast and axilla on physical examination. For patients without clinically suspicious axillary adenopathy, the primary tumor must be larger than 2 cm in diameter by physical exam or imaging studies (clinical T2-T3, N0-N1, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-3, N1-2, M0). T1N0M0 lesions are excluded. Patients with metastatic disease are excluded.
5. Patients without clearly defined palpable breast mass or axillary lymph nodes but radiographically measurable tumor masses are eligible. Accepted procedures for measuring breast disease are mammography, MRI, and breast ultrasound. Patients with lesions measurable only by imaging will require repeat imaging after 3 cycles and prior to surgery
6. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2
7. Neuropathy grade <1 by the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v 3.0)
8. Resolution of all acute effects of surgical procedures to grade ≤1.
For patients who had, or will have sentinel lymph node and/or axillary dissection prior to initiation of study treatment, completion at least 4 weeks prior to starting study treatment and well-healed wound is required
9. Adequate hematologic function with:
- Absolute neutrophil count (ANC) >1500/μL
- Platelets ≥100,000/μL
- Hemoglobin ≥10 g/dL
10. Adequate hepatic and renal function with:
- Serum bilirubin ≤ the institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x institutional ULN
- Alkaline phosphatase ≤2.5 x institutional ULN
- Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥40 mL/min
11. Left ventricular ejection fraction (LVEF) ≥50% by multigated acquisition (MUGA) or echocardiogram (ECHO)
12. Bilateral, synchronous breast cancer is allowed if one primary tumor meets the inclusion criteria
13. Knowledge of the investigational nature of the study and ability to provide consent for study participation
14. Ability and willingness to comply with study visits, treatment, testing, and other study procedures
1. Previous treatment for this breast cancer
2. Previous treatment with paclitaxel or carboplatin
3. Previous treatment with sunitinib or other angiogenic inhibitors (including, but not
limited to bevacizumab, sorafenib, thalidomide)
4. Any of the following within the 12 months prior to starting study treatment:
myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
graft, congestive heart failure, cerebrovascular accident including transient ischemic
attack, or pulmonary embolus
5. Uncontrolled hypertension (blood pressure >150/100 mmHg despite optimal medical
therapy)
6. Ongoing cardiac dysrhythmias grade ≥2, atrial fibrillation of any grade, or
prolongation of the QTc interval to >470 msec
7. Major surgery, significant traumatic injury, or radiation therapy within 4 weeks of
starting study treatment. An interval of at least 1week is required following minor
surgical procedures, with the exception of placement of a vascular access device
8. Grade 3 hemorrhage within 4 weeks of starting study treatment
9. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
the normal range with medication
10. Known human immunodeficiency virus (HIV) infection or other serious infection
11. Concomitant treatment with drugs having proarrhythmic potential including terfenadine,
quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol,
risperidone, indapamide, and flecainide
12. Concurrent use of the potent CYP3A4 inhibitors ketoconazole, itraconazole,
clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir,
amprenavir, indinavir, nelfinavir, delavirdine and voriconazole and CYP3A4 inducers
rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, St. John's
Wort, and dexamethasone. Use of dexamethasone for study premedication is allowed.
Grapefruit and grapefruit juice is prohibited. Alternative therapies should be used
when available. If use of a potent CYP3A4 inhibitor or inducer is necessary, this must
be approved by the Study Chair
13. Known or suspected hypersensitivity to drugs containing Cremophor®EL (polyoxyethylated
castor oil) such as cyclosporine or teniposide
14. Pregnancy or breast-feeding. Negative serum pregnancy test is required within 7 days
prior to first study treatment (Day 1, Cycle ) for all women of childbearing
potential. Patients of childbearing potential must agree to use a birth control method
that is approved by their study physician while receiving study treatment and for
three months after the last dose of study treatment. Patients must agree to not
breast-feed while receiving study treatment
15. Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal
agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator
(SERM). Patients must have discontinued use of such agents prior to beginning study
treatment
16. History of malignancy treated with curative intent within the previous 5 years with
the exception of skin cancer, cervical carcinoma in situ, or follicular thyroid
cancer. Patients with previous invasive cancers (including breast cancer) are eligible
if the treatment was completed more than 5 years prior to initiating current study
treatment, and there is no evidence of recurrent disease
17. Use of any investigational agent within 30 days of administration of the first dose of
study drug or concurrent treatment on another clinical study
18. Requirement for radiation therapy concurrent with study anticancer treatment. Patients
who require breast or chest wall radiation therapy after surgery are eligible, but
will have maintenance sunitinib interrupted while receiving radiation
19. Any other disease(s), psychiatric condition, metabolic dysfunction, or findings from a
physical examination or clinical laboratory test result that would cause reasonable
suspicion of a disease or condition, that contraindicates the use of study drugs, that
may increase the risk associated with study participation, that may affect the
interpretation of the results, or that would make the patient inappropriate for this
study
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Kagoshima,
- Akita,
- Washington, District of Columbia
- Baltimore, Maryland
- Badalona, Barcelona
- Madrid,
- Valencia,
- Oporto,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer | |||
Official Title ICMJE | Phase I/II Trial of Neoadjuvant Sunitinib Administered With Weekly Paclitaxel/Carboplatin in Patients With Locally Advanced Triple-Negative Breast Cancer | |||
Brief Summary | This trial will examine the combination of sunitinib plus paclitaxel and carboplatin as neoadjuvant treatment for locally advanced breast cancer. | |||
Detailed Description | This open label, Phase I/II trial is designed to evaluate the combination of sunitinib plus paclitaxel and carboplatin as neoadjuvant treatment for locally advanced breast cancer. The Phase I portion of this study will determine the maximum tolerated dose (MTD) of paclitaxel, sunitinib and carboplatin that can be used together as neoadjuvant treatment in patients with locally advanced breast cancer. The MTD identified in the Phase I portion of the study will be used in the Phase II portion which will evaluate the efficacy, safety, and tolerability of neoadjuvant sunitinib/paclitaxel/carboplatin given for 6 cycles in patients with locally advanced breast cancer. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 1 Phase 2 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Breast Cancer | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 54 | |||
Original Estimated Enrollment ICMJE | 53 | |||
Actual Study Completion Date ICMJE | September 2014 | |||
Actual Primary Completion Date | July 2013 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00887575 | |||
Other Study ID Numbers ICMJE | SCRI BRE 122 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | SCRI Development Innovations, LLC | |||
Study Sponsor ICMJE | SCRI Development Innovations, LLC | |||
Collaborators ICMJE | Pfizer | |||
Investigators ICMJE |
| |||
PRS Account | SCRI Development Innovations, LLC | |||
Verification Date | September 2016 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |